HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ozanezumab

targets Nogo-A

Also Known As:

GSK-1223249; GSK1223249

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bullman, Jonathan: 2 articles (01/2017 - 01/2015)
2.	Estrada, Ernesto: 1 article (10/2020)
3.	Boswell, Diane: 1 article (01/2017)
4.	Chio, Adriano: 1 article (01/2017)
5.	Davies, Matt: 1 article (01/2017)
6.	Desnuelle, Claude: 1 article (01/2017)
7.	Genge, Angela: 1 article (01/2017)
8.	Kiernan, Matthew C: 1 article (01/2017)
9.	Kim, Seung H: 1 article (01/2017)
10.	Lavrov, Arseniy: 1 article (01/2017)

Related Diseases

1.	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 01/01/2017 - "Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial." 01/01/2015 - "Ozanezumab dose selection for amyotrophic lateral sclerosis by pharmacokinetic-pharmacodynamic modelling of immunohistochemistry data from patient muscle biopsies."
2.	Stroke (Strokes) 01/01/2017 - "Two deaths were considered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and cerebrovascular accident in the placebo group). "
3.	Dyspepsia (Indigestion) 01/01/2017 - "Overall, reported adverse events, serious adverse events, and adverse events leading to permanent discontinuation of study drug or withdrawal from study were similar between the treatment groups, except for dyspepsia (ten [7%] in the ozanezumab group vs four [3%] in the placebo group), depression (11 [7%] vs five [3%]), and diarrhoea (25 [16%] vs 12 [8%]). "
4.	Transitional Cell Carcinoma 01/01/2017 - "Two deaths were considered related to the study drug (bladder transitional cell carcinoma in the ozanezumab group and cerebrovascular accident in the placebo group). "
5.	Respiratory Insufficiency (Respiratory Failure) 01/01/2017 - "At week 60, the number of deaths was higher in the ozanezumab group (20 [13%]) than in the placebo group (16 [11%]), mainly as a result of respiratory failure (ten [7%] vs five [3%]). "

Related Drugs and Biologics

1.	Procaine (Novocaine)
2.	Ellagic Acid
3.	Azacitidine (5 Azacytidine)
4.	silmitasertib
5.	volociximab
6.	romidepsin (FK228)
7.	amlexanox (Aphthasol)
8.	apabetalone